Applied Therapeutics Logo

Great News From HNF TRIAD Industry Partner — Applied Therapeutics

by | Aug 2, 2023 | 0 comments

Applied Therapeutics, Inc. has announced that their drug candidate, AT-007 (Govorestat), has received orphan medicinal product designation from the European Medicines Agency (EMA) for the treatment of Sorbitol Dehydrogenase (SORD) Deficiency. This designation reflects the high unmet medical need in SORD Deficiency and recognizes the benefit of Govorestat in reducing toxic sorbitol levels. New data published in the Journal of Clinical Investigation has further explained the molecular pathophysiology of SORD neuropathy and the role of sorbitol in neuronal toxicity. This is an important step for advancing regulatory initiatives in Europe and provides certain benefits and incentives for the development and marketing of the medicine.

Learn more on this topic

Related Blog Posts

Pharnext Announces PXT3003 for the Treatment of Charcot-Marie-Tooth Disease Type 1A has Been Granted Promising Innovative Medicine (PIM) Designation by UK Medicines and Healthcare Products Regulatory Agency

United Kingdom’s Medicine and Healthcare products Regulatory Agency (MHRA) has granted Promising Innovative Medicine (PIM) designation to its lead drug candidate, PXT3003, for the treatment of Charcot-Marie-Tooth Disease Type 1A (CMT1A) in patients 16 years and older.

Pharnext raises € 7.7 million in a private placement

Pharnext SA (FR0011191287 – ALPHA) (the “Company”), a biopharmaceutical company pioneering a new approach to developing innovative drug combinations based on its PLEOTHERAPY artificial intelligence platform harnessing big genomics data and network pharmacology, today announced a capital raise of circa € 7.7 million by way of issuance of 1,799,061 new ordinary shares (the “New Shares”) with one warrant attached each (together with the New Shares, the “ABSA”).

Join the conversation

Leave a Comment

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

Newsletter

Join for notifications on events, campaigns, & news